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ABSTRACT 
Trypanosoma cruzi and Helicobacter pylori (HP) are pathogens that cause chronic diseases 
and have been associated with hypergastrinemia. The aim of this study was to evaluate the 
fasting gastrin levels in patients with different clinical forms of Chagas disease (CD), coinfected 
or not by HP. The enrolled individuals were outpatients attending at the university hospital. HP 
infection was assessed by serology and 13C-urea breath test. Fasting serum gastrin concentration 
was measured by chemiluminescence assay. Gastric endoscopic and histological features were 
also evaluated. Associations between CD and serum gastrin level were evaluated in a logistical 
model, adjusting for age, gender and HP status. A total of 113 patients were evaluated (45 
with Chagas disease and 68 controls). In the multivariate analysis, increasing serum gastrin 
levels (OR= 1.02; 95% CI= 1.01-1.12), increasing age (OR= 1.05; 95% CI= 1.02 - 1.09) and 
HP-positive status (OR = 2.88; 95% CI = 1.10 - 7.51) remained independently associated 
with CD. The serum gastrin levels were significantly higher in the group of patients with the 
cardiodigestive form (P = 0.03) as well as with digestive form (P = <0.001) of Chagas disease 
than in the controls. In conclusion, patients with cardiodigestive and digestive clinical forms 
of CD have increased basal serum gastrin levels in comparison with controls. Moreover, we 
also demonstrated that H. pylori coinfection contributes to the hypergastrinemia shown in CD.
KEYWORDS: Helicobacter pylori. Chagas disease. Gastrin. Chronic gastritis. Acid 
secretion. Gastric physiology.
INTRODUCTION 
Chagas disease, caused by the intracellular protozoan Trypanosoma cruzi 
(T. cruzi), is endemic in Latin American countries where it is primarily transmitted 
to humans by contact with faeces of triatomine vectors1. In the past decades, the 
migration of populations from endemic areas has contributed to the spread of Chagas 
disease to the USA, Canada, many European and some Western Pacific countries2.
The acute phase of Chagas disease is usually asymptomatic, although a high 
number of parasites circulate in the bloodstream of infected individuals. Then, the 
disease progresses to an asymptomatic chronic phase called the indeterminate form, 
which is prolonged and a few or no parasites are found in blood. Commonly, around 
20% to 30% of infected patients will develop irreversible cardiovascular and/or 
gastrointestinal lesions with damage on enteric nervous system. These alterations 
characterize the symptomatic forms of chronic Chagas disease, i.e., cardiac, digestive 
or cardiodigestive form1,3.
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An abnormally high fasting serum gastrin level associated 
with hyposecretion of gastric acid has been reported in 
chagasic patients with the digestive form4-8. Gastrin, a 
hormone produced in G cells mainly located in the gastric 
antral mucosa, is a potent secretor of gastric acid. Histamine 
and acetylcholine, released from enterochromaffin-like cells 
and from enteric neurons, respectively, also stimulate the acid 
secretion while somatostatin, secreted by oxyntic and antral 
D cells, is the major inhibitor of acid secretion9. Indeed, the 
regulation of gastric acid secretion in parietal cells is achieved 
by a highly coordinated interaction among neural, hormonal 
and paracrine pathways. 
Gastrin may be increased in other various clinical 
conditions such as the gastric infection with Helicobacter 
pylori (H. pylori)10. This Gram-negative bacterium is 
recognized as the main cause of chronic gastritis throughout 
the world and develops an important role in peptic ulcer, 
gastric carcinoma and mucosa-associated lymphoid tissue 
(MALT) lymphoma11. H. pylori (HP) causes diverse effects 
on gastric acid secretion depending mainly on the location 
within the stomach and the degree of inflammation. Usually, 
antral predominant gastritis results in hypersecretion of 
acid and can lead to duodenal ulceration. The predominant 
gastritis on corpus or pangastritis results in atrophic gastritis 
and abnormally low secretion of gastric acid associated with 
marked hypergastrinemia. These alterations can strongly 
favor the development of gastric adenocarcinoma10,12-14. 
Studies showing an increased basal serum gastrin levels 
in patients with Chagas disease evaluated only the digestive 
form of the disease and most of them were conducted before 
the discovery of H. pylori, which has been shown to be 
highly prevalent in chagasic patients. Thus, the aim of this 
study was to evaluate whether fasting hypergastrinemia 
also occurs in patients with other clinical forms of Chagas 
disease, coinfected or not with H. pylori. 
MATERIAL AND METHODS
This cross-sectional study was approved by the Ethics 
Committee of the Federal University of Triangulo Mineiro 
and was conducted in accordance with the Declaration 
of Helsinki. All volunteers signed the informed consent 
form and answered a questionnaire to obtain the social-
demographic data. Clinical information was obtained by 
reviewing the patients’ medical records.
Subjects and clinical samples
A total of 113 outpatients (45 with Chagas disease and 
68 without Chagas Disease (CD) – controls) attended at 
the university hospital from April 2012 to January 2015 
were evaluated. The exclusion criteria were previous 
therapy for H. pylori eradication, history of peptic ulcer, 
gastrointestinal cancer, renal failure or concomitant severe 
illness. Individuals taking proton pump inhibitors, H2 
blockers and H2-antihistamines or those who underwent 
upper gastrointestinal tract surgery were also excluded. 
A blood sample was collected from each patient under 
fasting conditions for the gastrin measurements, serological 
diagnosis of Chagas disease and H. pylori infection. 
Additionally, all patients were submitted to 13C-urea breath 
test (13C-UBT) for H. pylori diagnostic. 
Diagnosis of Chagas disease
Enzyme-linked immunosorbent assay (ELISA; 
Chagatest ELISA-WIENER, Rosario, Argentina), passive 
hemagglutination (Chagatest HAI-WIENER, Rosario, 
Argentina) and indirect immunofluorescence tests 
(Imuno-Con Chagas-WAMA, Sao Carlos, Brazil) were 
performed according to the manufacturer’s instructions. 
Chagasic patients showed positive reactions to at least two 
serological tests and control patients were negative by the 
three tests. Chagasic patients were classified according to 
the clinical form of disease (i.e., indeterminate, digestive, 
cardiac or cardiodigestive) based on clinical examination, 
electrocardiography and radiological exams of the chest, 
esophagus and colon. 
H. pylori status
H. pylori infection was assessed by serology and 
13C-UBT. Patients with discordant results were excluded. 
Patients were considered H. pylori-positive (HP-positive) if 
both tests were positive and H. pylori-negative (HP-negative) 
if both tests were negative. IgG antibodies specific to 
H. pylori were detected using a commercial ELISA kit 
(Serion Immundiagnostica GmbH, Würzburg, Germany), 
according to the manufacturer’s instructions and results 
were expressed as positive or negative. The 13C-UBT was 
performed after an overnight fast. After collection of a basal 
breath sample, an oral dose of 13C-urea on a citric acid 
base was administered. An additional breath sample was 
collected after 30 min. Breath samples were analyzed using 
an isotope-selective non-dispersive infra-red spectrometer 
(NDIRIS; Wagner Analytical Systems, Bremen, Germany). 
A change >4.0‰ in delta over baseline (DOB) was 
considered HP-positive. 
Measurements of serum gastrin levels 
Gastrin-17 concentration was measured by a chemi-
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luminescence assay (IMMULITE® 2000 immunoassay 
system; Siemens Medical Solutions Diagnostics, Los 
Angeles, EUA) and the values were expressed in pg/mL. 
All gastrin assays were performed in duplicate. The normal 
value for fasting gastrin-17 using this assay is <115 pg/mL. 
Histological analysis
Endoscopic biopsy specimens were obtained from 
the antrum and corpus of the stomach of patients who 
underwent EGD by medical indication. Biopsy samples 
were fixed overnight in buffered formalin embedded 
in paraffin, sliced to 4 µm thickness, and stained with 
haematoxylin and eosin for histological examination. The 
Warthin-Starry staining was used for detection of spiral 
H. pylori. The degree of gastric mucosal inflammation and 
activity were also assessed. The location of gastritis was 
classified according to the presence of mononuclear cells 
in the antrum, corpus or in both. Glandular atrophy and 
intestinal metaplasia were classified as absent or present. 
Statistical analysis
The association of Chagas disease with the basal serum 
gastrin level (dependent variable) including H. pylori status, 
age and gender (independent variables) was tested by a 
univariate analysis. All variables with P values ≤ 0.25 were 
included in the full model of the logistic regression. Odds 
ratios (OR) and 95% confidence intervals (CI) were used as 
an estimate of the risk. The Hosmer-Lemeshow goodness-
of-fit test was used to evaluate the fitness of the model15. In 
addition to visual examination of histograms and box plots, 
the Kolmogorov-Smirnov (K-S) test or Shapiro-Wilk (SW) 
test, based on the number of each subgroups, was used for 
assessing the normality of data. Because data did not show a 
normal distribution even after log transformation, a two-tailed 
Mann-Whitney U-test (median / range) was used to detect the 
difference of serum gastrin levels among groups. Otherwise, 
because the age of participants was normally distributed, the 
groups were compared by a two-tailed Student’s T test (mean 
/ standard deviation). Data were analyzed with the statistical 
package for the social sciences (SPSS) version 23.0 (SPSS 
Inc., Chicago, IL, USA). For comparison of groups with 
dichotomous variables the two-tailed chi-squared test (with 
Yates’ correction) or the Fisher´s exact test was used. P value 
≤0.05 was considered significant. 
RESULTS
Demographic data 
Among the 113 included subjects, 45 were chagasic 
patients (14 men and 31 women; mean age 64.3 ± 10.5 
years) and 68 were controls without CD (29 male and 
39 female; mean age 60.4 ± 10.1 years). When the groups 
were compared, no difference was observed regarding the 
gender (P = 0.29; OR = 1.65; 95% CI = 0.74 - 3.64), but 
the disease group participants were older than the control 
ones (P = 0.05). Most chagasic (35 - 77.8%) patients and 
controls (43 - 63.2%) were HP-positive.
Median gastrin levels 
Median serum gastrin levels were higher in chagasic 
patients than in controls, both in HP-positive patients 
(65.10 pg/mL; range, 11-557 pg/mL vs. 39.80 pg/mL; range, 
12-172 pg/mL, respectively; P = 0.01) and HP-negative ones 
(49.15 pg/mL; range, 16-670 pg/mL vs. 23.0 pg/mL; range, 
10-133 pg/mL, respectively; P = 0.009), but higher in the 
HP-positive groups than in the negative ones.
In order to identify variables independently associated 
with Chagas disease, data were analyzed in a logistic 
regression model. In the univariate analysis, the basal 
serum gastrin level, HP status and age, but not the gender, 
were selected. In the multivariate analysis, the increasing 
of serum gastrin levels, the increasing age and HP-positive 
status remained independently associated with Chagas 
disease (Table 1).
Table 1 - Variables associated with Chagas disease (n=45) in comparison with controls (n=68) in a multivariate analysis.
Variables
Univariate Multivariate
P value OR 95% CI P value
Gender 0.29
Increasing age 0.05 1.05 1.02-1.09 0.04
H. pylori + status 0.09 2.88 1.10-7.51 0.03
Increasing gastrin level 0.008 1.02 1.01-1.12 0.03
The Hosmer-Lemeshow test showed good fitness of the logistic regression model (P = 0.25; 8 degrees of freedom; 10 steps). 
+ positive; OR- odds ratio; 95% CI- 95% confidence interval.
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Among chagasic patients, 10 (22.2%) had the 
cardiodigestive form, 12 (26.7%) the digestive form, 
12 (26.7%) the indeterminate form, and 11 (24.4%) the 
cardiac form of the disease. Figure 1 shows the basal serum 
gastrin levels of controls and of patients with different 
clinical forms of Chagas disease. Serum gastrin levels 
were significantly higher in the group of patients with the 
cardiodigestive form as well as with the digestive form of 
disease than in the control group. 
Nevertheless, no difference was observed between 
controls and patients with either the indeterminate 
(P = 0.53) or the cardiac (P = 0.13) forms of disease. Also, 
in the group of chagasic patients, significant higher levels 
of serum gastrin were observed in the digestive than in the 
cardiac (P = 0.008) and in the indeterminate (P = 0.01) 
forms of the disease. In addition, the cardiodigestive form of 
the disease did not differ from the digestive one (P = 0.65). 
No significant difference was observed in respect to the 
prevalence of HP and age among different subgroups of 
clinical forms of Chagas disease (P> 0.05).
In the subgroup of patients who underwent EGD 
(n = 35), serum gastrin levels were significantly higher 
(P = 0.004) in the nine patients with the digestive clinical 
form of Chagas disease (median, 72.20 pg/mL; range, 36-246 
pg/mL) than in the 26 controls (median, 32.20 pg/mL; 
range, 11 - 133 pg/mL). Histological exams detected the 
presence of the bacterium in both, the antral and the oxyntic 
gastric mucosa in seven (77.8%) chagasic patients and in 
13 (50.0%) controls (P = 0.29; OR = 3.50; 95% CI = 0.61 
– 20.13). Gastritis was observed in the gastric mucosa of 
all HP-positive patients, without differences in the number 
of either mononuclear or polymorphonuclear cells between 
chagasic and control patients (P = 1.0 for both, two tailed 
Fisher exact test). Chagasic patients (n= 4; 44.4%) did 
not differ from controls (n= 5; 19.2%) in respected to the 
presence of intestinal metaplasia in the stomach mucosa 
(P = 0.58; OR = 2.17; 95%CI = 0.45 - 10.49). Gastric or 
duodenal peptic ulcer was not observed in chagasic patients. 
DISCUSSION
The findings of the present study showed that basal 
serum gastrin levels are higher in patients with Chagas 
disease than in non-chagasic controls. This result persisted 
even after adjustment for potential confounding factors such 
as age, gender and HP infection. It should be noted that, 
for the first time, it was demonstrated that hypergastrinemia 
is present in the cardiodigestive clinical form of Chagas 
disease as well as in digestive form. 
It is known that rising intraluminal pH of the stomach 
is the main factor stimulating gastrin production and 
secretion. However, the abnormal high gastrin levels found 
in chagasic patients with the digestive clinical form has 
been attributed to the low gastric acid secretion caused by 
a partial denervation of the stomach, thereby affecting the 
parasympathetic stimulation4-8.The role of vagal nerves 
in the stimulation of gastric acid secretion in humans is 
complex, but it is known that acetylcholine released from 
these nerves has a direct stimulatory effect on parietal 
cells14. It has been demonstrated that acid hyposecretion 
and stomach nervous tissue injury are present mainly in the 
digestive form of Chagas disease. Both conditions can also 
occur in the cardiodigestive form, as patients presenting 
with either of these clinical forms of Chagas disease 
showed significant higher levels of gastrin in comparison 
with controls. Notably, the cardiodigestive form showed 
wide values of basal serum gastrin, but without significant 
difference with the digestive form. 
Other mechanisms could also be involved in the 
increase of serum gastrin levels observed among chagasic 
patients such as reduced somatostatin secretion, because 
the significant decrease in the number of antral D-cells 
observed in CD patients could lead to hypergastrinemia in 
these patients. Likewise, patients infected with H. pylori 
have abnormal regulation of gastrin secretion due to lower 
somatostatin concentrations16-19 in the antral region of the 
stomach. Moreover, the eradication of H. pylori results in the 
resolution of the gastritis and associated abnormalities17,18,20. 
Figure 1 - Box plots representing the basal serum gastrin levels 
among the control and chagasic patients with different clinical 
forms of the Chagas disease. The horizontal bar across the box 
indicates the median and the capped bars indicate the minimum 
and maximum data values. The upper and lower limits of the 
boxes represent the 75th and 25th percentiles, respectively. 
No difference was observed between the controls and the 
indeterminate (P = 0.53) and cardiac (P = 0.13) forms of the 
disease. Also, the cardiodigestive clinical form did not differ 
from the digestive form (P = 0.65). The data were analyzed by 
the two-tailed Mann-Whitney U test.
Rev Inst Med Trop São Paulo. 2019;61:e7
Increased serum gastrin in patients with different clinical forms of Chagas disease coinfected with Helicobacter pylori
Page 5 of 6
A high prevalence of coinfection with H. pylori was 
observed among patients with Chagas disease in this 
study (approximately 78%) and in others, irrespective of 
the clinical form of the disease21-26. In the histological 
evaluation, we observed that H. pylori infection was spread 
into the antral and corpus of gastric mucosa in the majority 
of patients with the digestive form of Chagas disease, which 
may also contribute to gastric atrophy, hypochlorydria 
and hypergastrinemia26. Thus, the hypergastrinemia that 
occurs in H. pylori-infected individuals has been attributed 
to hypochlorhydria, decreased secretion of somatostatin 
associated with the production of pro-inflammatory cytokines 
such as IL8, IL1β and TNFα, and also by a putative direct 
induction of the gastrin gene expression by the bacterium 
itself, especially the more virulent strains10,13,27.
Taking into account all these considerations, H. pylori 
gastric infection can contribute to the hypergastrinemia 
found in Chagas disease. In the present study, we 
demonstrated, using a logistic regression analysis, that 
H. pylori infection was not a confounding factor in the 
increased gastrin levels results observed in Chagas disease. 
The gastric physiological changes that could be caused 
by a long term coinfection with H. pylori and T. cruzi are 
completely unknown, but various effects and individual 
variations can be expected. Therefore, further studies are 
necessary to clarify the real contribution of the bacterium in 
the elevated gastrin levels, in chronic Chagas disease. The 
treatment of chagasic patients coinfected with H. pylori 
and the measurement of their basal gastrin levels after the 
eradication of the bacterium could bring some highlights 
on this matter. Among non-chagasic patients, it has been 
demonstrated that the level of gastrin decreases after 
H. pylori eradication therapy17,18,20,28.
A better understanding of the real influence of H. pylori 
infection on gastrin levels in Chagas disease should 
lead to an improved management of coinfected patients. 
Furthermore, as chagasic patients usually have various 
dyspeptic symptoms and are H. pylori coinfected, the 
diagnosis of H. pylori infection and the corresponding 
eradication therapy should be considered in order to reduce 
the gastrointestinal symptoms and probably gastrin levels. 
Pinazzo et al.24 reported the resolution or improvement 
of upper gastrointestinal symptoms in more than 70% of 
chagasic patients treated for H. pylori infection resulting 
in a clearer delineation of symptoms directly induced by 
T. cruzi infection.
The findings of the present study showed that basal 
serum gastrin levels are higher in patients with Chagas 
disease than in the non-chagasic ones (controls) even after 
adjustment for potential confounding factors such as age, 
gender and HP infection. Additionally, it was demonstrated, 
for the first time, that hypergastrinemia is present in the 
cardiodigestive clinical form of Chagas disease as well as 
in the digestive form.
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